In addition, myeloid-associated genes (COX2, IL8, IL1B) in the tumor and circulating cytokines (IL-8 and IL-6) were associated with resistance and shorter OS in urothelial bladder cancer patients treated with anti-PD-L1 (Atezolizumab or Durvalumab) (105–108). This evidence concerns the gene CXCL8 and bladder transitional cell carcinoma.